Home/Investors/Fairmount

Fairmount

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$240M

Focus Areas

6

Top Stage

Phase 1b

Investment Focus

Allergy & Immunology Inflammatory Diseases Fibrotic Diseases Immunology Respiratory Dermatology

Portfolio Companies

Company	Stage	Valuation	Focus
Third Harmonic Bio	Phase 1b	$240M	Allergy & Immunology, Inflammatory Diseases
Mirador Therapeutics	preclinical	—	Immunology, Respiratory

Frequent Co-Investors

OrbiMed2 shared Atlas Venture1 shared ARCH Venture Partners1 shared Redmile Group1 shared New Enterprise Associates (NEA)1 shared Venrock Healthcare Capital Partners1 shared